Akebia Therapeutics, Inc. To Host Conference Call And Slide Webcast Following Presentation Of AKB-6548 Phase 2b Study Results At International Society of Nephrology’s World Congress Of Nephrology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA) a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that it will host a conference call and slide webcast on Monday, March 16, 2015, at 8:30 a.m. Eastern Time to discuss the results of its Phase 2b study of AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease (CKD).

Help employers find you! Check out all the jobs and post your resume.

Back to news